非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂（英文）演示文稿.ppt

Epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer;Survival(anti-apoptosis);R;IDEAL 1 and 2 trial design;Median time to improvement - symptoms and QOL;IDEAL 1 and 2: overall survival by symptom improvement (250 mg/day);ISEL (IRESSA Survival Evaluation in Lung Cancer): Clinical Trial Design;ISEL - Overall Survival;ISEL Survival: Orientals;J Chemother 2005;17:679;Study Design of BR.21;BR.21: Significant clinical predictors of response to Tarceva;Improvement in Survival with Tarceva;BR.21: Time to symptom deterioration (months);TRUST: Tarceva MO18109An expanded access clinical program of Tarceva (erlotinib) in pts with advanced stage IIIB/IV NSCLCLung Cancer 2008;Patient Population Response;Response rate and control rate by pretreatment characteristics and skin toxicity ;0.00;EGFR-TKI vs. chemotherapeutic agents in salvage chemotherapy;In conclusion, both chemotherapeutic agents, such as docetaxel alone or gemcitabine + vinorelbine, and gefitinib, are appropriate salvage regimens for Chinese NSCLC pts who have failed previous chemotherapy. However, gefitinib has a better safety profile and probably better survival than the chemotherapeutic agents, and would be an appropriate alternative choice for salvage chemotherapy, even in a second-line setting for Chinese pts. ;Efficacy of Salvage Therapy in NSCLC;Salvage Chemotherapy (n=342) Grade ? Neutroopenia;Salvage Chemotherapy (n=342) Grade ? Fatigue;Interest;Interest;Interest;Interest;Clinical characteristics response rate (pt number=1974);EGFR Mutation;Failure of Doublet Chemotherapy plus EGFR-TKI;Giaccone. JCO 2004;22:777;Can we further prolong disease-free survival and overall survival ?;Date;Conclusions;% Free from Progression;Erlotinib induces G1 arrest which can block M-phase activity of docetaxel;First-line Asian Sequential Tarceva plus Chemotherapy Trial (FAST-ACT): Study Design;Time to Disease Progression;First line treatment with EGFR-TKIs in those with EGFR mutated pa